echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > $500 million: Lilly introduces Nimbus' AMPK activator

    $500 million: Lilly introduces Nimbus' AMPK activator

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 11, 2022, Nimbus Therapeutics announced a collaboration agreement with Eli Lilly to jointly develop an AMPK activator developed by Nimbus for the treatment of metabolic diseases
    .
    Under the agreement, Lilly will pay up to $496 million in research and development expenses plus potential milestone payments, in addition to a percentage share
    of sales.

    AMPK activator is one of
    Nimbus' core pipelines.

    The AMPK signal path is shown in
    the figure below.

    AMPK, AMP-dependent protein kinase, is a key molecule in the regulation of energy metabolism and one of the core of
    research on diabetes and other metabolism-related diseases.
    AMPK is widely expressed in various metabolism-related organs, including fat, brain, muscle, heart, kidney, liver, etc
    .

    Academician Lin Shengcai is an expert in the study of AMPK pathway, and in February 2022, Lin Shengcai's team published an article in Nature and found that PEN2 is the target of metformin, and metformin activates the AMPK pathway
    through PEN2.

    In October this year, Lin Shengcai's team published a research article
    on Aldometanib, a new AMPK activator.

    summary

    summary

    AMPK activator has great potential in the treatment of metabolic diseases such as diabetes, NAFLD, and obesity, and with the clarity of mechanism research, translational research has also entered an accelerated stage, and has attracted more and more attention
    from multinational pharmaceutical companies.

    Original link:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.